Published: 2017-10-16

From the carrier of active substance to drug delivery systems

Posnan University of Medical Sciences
carrier drug delivery system sustained release zero-order kinetic nanoparticle

Abstract

Development and innovation all the time are in interests of pharmaceutical science and evaluation of different dosage forms. They are concerned with the aim of compliance of patients. All the time different research groups try to develop and improve form of drugs to receive better bioavailability or strict control of dose, place and time of action of active substances. This is possible by using different excipients; biodegradable, biocompatible polymers that work like a carriers; developing simple drug delivery systems, which in time became more and more complicated; nanotechnology that control size, shape and multi-functionality of particulate drug delivery systems. This review shows the main points in the evaluation of pharmaceutical researches from simple carriers of active substances to drug delivery systems.

Downloads

Download data is not yet available.

References

  1. Hoffman AS. The origins and evolution of “controlled” drug delivery systems. J Contr Rel. 2008;132:153–163.
  2. Lee BK, Yun YH, Park K. Smart Nanoparticles for Drug Delivery: Boundaries and Opportunities. Chem Eng Sci. 2015;24(125):158–164.
  3. Anselmo AC, Mitragotri S. An Overview of Clinical and Commercial Impact of Drug Delivery Systems. J Control Rel. 2014;28(190):15–28.
  4. Krówczyński L. Postacie leku o przedłużonym działaniu. Warszawa PZWL; 1980. p. 64–114.
  5. Romansky MJ, Rittman GE. Method of Prolonging Action of Penicillin. Science. 1944;100:196–198.
  6. Romansky MJ, Rittman GE. Penicylin blood levels for 24 hours following the single intramuscular injection of Calcium Penicyline in Beeswax and Peanut Oil. New England J M. 1945;233:577–582.
  7. Choay A, Choay H. Prolingation des effets de l’insuline par association á la polyvinylpyrrolidone. Ann phsarm franc. 1947;5:420–429.
  8. Chaudhary NC and Saunders L. Sustained release of drugs from ion-exchange resins. J Pharm Pharmacol. 1956;8:975–986.
  9. Robinson MJ, Swintosky JV. Sulfaethylthiadiazole V. Design and study of an oral sustained release dosage form. J Pharm Sci. 1959;48(8):473–478.
  10. Keating JW. Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment there with. 1961. US Patent 2,990,332.
  11. Hays EE. Pharmaceutical compositions containing a resin narcotic compound. 1961. US Patent 3,035,979.
  12. Keating JW. Pharmaceutical preparations comprising phosphorous containing cation-exchange resins having a basic drug adsorbed thereon; and treatment tere with. 1964. US Patent 3,143,465.
  13. Folkman J, Long DM. The use of silicone rubber as a carrier for prolonged drug therapy. Surg Res. 1964;4:139–142.
  14. Bangham AD, Horne RH. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol. 1964;8(5):660–668.
  15. Folkman J, Long DM, Rosenbau R. Silicone rubber – a new diffusion property useful for general anesthesia. Science. 1966;154:148–149.
  16. Schmitt E, Polistina R. Surgical sutures. 1967. US Patent 3,297,033.
  17. Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature. 1976;263:797–800.
  18. Zaffaroni A. Bandage for administering drugs. 1971. US Patent 3,598,122.
  19. Boswell G, Scribner R. Polylactide-drug mixtures. 1973. US Patent 3,773,919.
  20. Gregoriadis G, Swain CP, Wills EJ, Tavill AS. Drug carrier potential of liposomes in cancer chemotherapy. Lancet. 1974;1:1313–1316.
  21. Gregoriadis G. The carrier potential of liposomes in biology and medicine. N Eng J Med. 1976;295:704–710.
  22. Kreuter J, Speiser P. In vitro studies of poly-(methylmethacrylate) adjuvants. J Pharm Sci. 1976;65:1624–1627.
  23. Buhleier E, Wehner W, Vogtle F. Cascade- and nonskid-chain-like syntheses of molecular cavity topologies. Synthesis. 1978;2:155–8.
  24. Tomalia DA, Baker H, Dewald JR, Hall M, Kallos G, Martin S, et al. A new class of polymers: starburst dendritic macromolecules. Polymer J. 1985;17:117–32.
  25. Duncan R, Kopecek J. Soluble synthetic-polymers as potential-drug carriers. Adv Polymer Sci. 1984;57:51–101.
  26. Iwai K, Maeda H, Konno T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res. 1984;44(5):2115–2121.
  27. Yokoyama M, Miyauchi M, Yamada N, Okano T, Sakurai Y, Kataoka K, et al. Polymer micelles as novel drug carrier – adriamycin-conjugated poly(ethylene glycol) poly(aspartic acid) block copolymer. J Control Rel. 1990;11:269–278.
  28. Schwarz C, Mehnert W, Lucks JS, Müller RH. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Rel. 1994;30(1):83–96.
  29. Sriwongjanya M, Bodmeier R. Effect of ion exchange resins on the drug release from matrix tablets. Eur J Pharm Biopharm. 1998;46:321–327.
  30. Peppas NA, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm. 2000;50(1):27–46 .
  31. Cheng Y, Xu Z, Ma M, Xu T. Dendrimers as Drug Carriers: Applications in Different Routes of Drug Administration. J Pharm Sci. 2008;97(1):123–143.
  32. Grill AE, Johnston NW, Sadhukha T, Panyam J. A review of select recent patents on novel nanocarriers. Recent Patents on Drug Delivery and Formulation. 2009;3(2):137–142.
  33. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2:347–360.
  34. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13(11):813–827.
  35. Kowalczuk A, Trzcinska R, Trzebicka B, Müller AHE, Dworak A, Tsvetanov CB. Loading of polymer nanocarriers: Factors, mechanisms and applications. Prog Poly Sci. 2014;39:43–86.
  36. Čerpnjak K, Zvonar A, Gašperlin M, Vrečer F. Lipid-based systems as a promising approach for enhancing the bioavailability of poorly water-soluble drugs. Acta Pharm. 2013;63:427–445.
  37. Dening TJ, Rao S, Thomas N, Prestidge CA. Novel Nanostructured Solid Materials for Modulating Oral Drug Delivery from Solid-State Lipid-Based Drug Delivery Systems. The AAPS Journal. 2016;18(1). DOI: 10.1208/s12248-015-9824-7.
  38. Rigon RB, Oyafuso MH, Fujimura AT, Gonçalez AL, do Prado AH, Gremiao APD, et al. Nanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A Review. BioMed Research Inter. 2015 Article ID 841817, 22 pages; DOI: http://dx.doi.org/10.1155/2015/841817.
  39. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature Rev Drug Discov. 2005;4(2):145–160.
  40. Mahore JG, Wadher KJ, Umekar MJ, Bhoyar PK. Ion exchange resins: pharmaceutical applications and recent advancement. Int J Pharm Sci Rev Res. 2010;1(2):8–13.
  41. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36–48.
  42. Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Poly Sci. 2014;39:268–307.
  43. Bhadra D, Yadav AK, Bhadra S, Jain NK. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int J Pharm. 2005;295:221–33.
  44. Villiers A. Sur la fermentation de la fécule par l’action du ferment butyrique. C R Acad Sci. 1891;112:536–538.
  45. Kurkov SV, Loftsson T. Cyclodextrins. Inter J Pharm. 2013;453:167–180.
  46. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov. 2004;3:1023–1035.
  47. Vallet-Regí M, Balas F, Arcos D. Mesoporous Materials for drug delivery. Angew Chem Int. 2007;46:7548–7558.

How to Cite

1.
Jadach B. From the carrier of active substance to drug delivery systems. JMS [Internet]. 2017Oct.16 [cited 2020Aug.5];86(3):231-6. Available from: https://jms.ump.edu.pl/index.php/JMS/article/view/198